Methylthiouracil

Methylthiouracil
Clinical data
AHFS/Drugs.com International Drug Names
ATC code H03BA01 (WHO)
Identifiers
CAS Number 56-04-2
PubChem (CID) 667493
ChemSpider 580871
UNII QW24888U5F YesY
KEGG C19265 YesY
ChEMBL CHEMBL1330588
ECHA InfoCard 100.000.230
Chemical and physical data
Formula C5H6N2OS
Molar mass 142.18 g/mol
3D model (Jmol) Interactive image
  (verify)

Methylthiouracil is an antithyroid preparation. It is a thioamide, closely related to propylthiouracil.

Methylthiouracil is not used clinically in the United States, it has a similar mechanism of action and side effect to that of propylthiouricil.

The drug acts to decrease the formation of stored thyroid hormone, as thyroglobulin in the thyroid gland.

The clinical effects of the drug to treat the hyperthyroid state can have a lag period of up to two weeks, depending on the stores of thyroglobulin and other factors.

Side effects

Agranulocytosis: develops rapidly, sore throat and fever are hallmark symptoms. Can be fatal if drug is not discontinued promptly.

Allergic skin reactions the most dangerous of which is exfoliative dermatitis, it rapidly can get out of control, notify the physician should a skin eruption occur.

Hepatitis: yellowing of the skin, nausea, yellowing of the whites of the eyes, flu-like symptoms.

Thrombocytopenia: unusual bruising or bleeding.

Synthesis

Methylthiouracil synthesis:[1]

Methylthiouracil is prepared quite simply by condensation of ethyl acetoacetate with thiourea.

Further work in this series shows that better activity was obtained by incorporation of a lipophilic side chain.

References

  1. R. List, Justus Liebigs Ann. Chem., 236, 1 (1886).


This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.